{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT06343402","nct_id":"NCT06343402","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06343402. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) as monotherapy","label":"Cohort 1a - Dose Escalation/Dose Finding Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) in combination with pembrolizumab infusion (IV)","label":"Cohort 1b - Dose Escalation/Dose Finding Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) as monotherapy","label":"Cohort 2a - Dose Expansion Monotherapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with pembrolizumab infusion (IV)","label":"Cohort 2b - Dose Expansion Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD)","label":"Cohort 1b Safety Lead-In - Dose Expansion Doublet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD)","label":"Cohort 1b - Dose Expansion Doublet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD) and pembrolizumab infusion (IV)","label":"Cohort 1b Safety Lead-In - Dose Expansion Triplet Combination Therapy","type":"EXPERIMENTAL"},{"description":"Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with BBO-10203 once a day (QD) and pembrolizumab infusion (IV)","label":"Cohort 1b - Dose Expansion Triplet Combination Therapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-09","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer","NSCLC","KRAS G12C","Metastatic Lung Cancer","Advanced Lung Carcinoma"],"enrollment":{"count":350,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BBO-8520","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"BBO-10203","type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","official_title":"A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2031-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Adverse Events","timeFrame":"approximately 3 years"},{"measure":"Dose-limiting toxicities (DLTs)","timeFrame":"approximately 3 years"}],"references":[],"start_date":{"date":"2024-05-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06343402"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06343402"}